These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Putative mechanisms of action of statins in multiple sclerosis--comparison to interferon-beta and glatiramer acetate. Neuhaus O; Stüve O; Archelos JJ; Hartung HP J Neurol Sci; 2005 Jun; 233(1-2):173-7. PubMed ID: 15949504 [TBL] [Abstract][Full Text] [Related]
28. [Current concepts on the use of some immunomodulatory drugs in the treatment of multiple sclerosis]. Correale J; Cristiano E Medicina (B Aires); 2001; 61(4):470-80. PubMed ID: 11563177 [TBL] [Abstract][Full Text] [Related]
29. Treatment and treatment trials in multiple sclerosis. Kieseier BC; Wiendl H; Hemmer B; Hartung HP Curr Opin Neurol; 2007 Jun; 20(3):286-93. PubMed ID: 17495622 [TBL] [Abstract][Full Text] [Related]
30. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Krumbholz M; Faber H; Steinmeyer F; Hoffmann LA; Kümpfel T; Pellkofer H; Derfuss T; Ionescu C; Starck M; Hafner C; Hohlfeld R; Meinl E Brain; 2008 Jun; 131(Pt 6):1455-63. PubMed ID: 18474519 [TBL] [Abstract][Full Text] [Related]
31. Immunopathogenesis and immunotherapeutic approaches in multiple sclerosis. Lim ET; Giovannoni G Expert Rev Neurother; 2005 May; 5(3):379-90. PubMed ID: 15938671 [TBL] [Abstract][Full Text] [Related]
32. Apolipoprotein alleles and the response to interferon-β-1b in multiple sclerosis. Carmona O; Masuet C; Alía P; Moral E; Alonso-Magdalena L; Casado V; Martín-Ozaeta G; Arbizu T Eur Neurol; 2011; 65(3):132-7. PubMed ID: 21325856 [TBL] [Abstract][Full Text] [Related]
33. Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs. Gilli F; Bertolotto A; Sala A; Hoffmann F; Capobianco M; Malucchi S; Glass T; Kappos L; Lindberg RL; Leppert D Brain; 2004 Feb; 127(Pt 2):259-68. PubMed ID: 14607790 [TBL] [Abstract][Full Text] [Related]
34. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews. Clerico M; Rivoiro C; Contessa G; Viglietti D; Durelli L Clin Neurol Neurosurg; 2008 Nov; 110(9):878-85. PubMed ID: 18164542 [TBL] [Abstract][Full Text] [Related]
36. Pharmacogenomics of IFN-beta in multiple sclerosis: towards a personalized medicine approach. Vosslamber S; van Baarsen LG; Verweij CL Pharmacogenomics; 2009 Jan; 10(1):97-108. PubMed ID: 19102719 [TBL] [Abstract][Full Text] [Related]
37. Lessons from randomised direct comparative trials. Achiron A; Fredrikson S J Neurol Sci; 2009 Feb; 277 Suppl 1():S19-24. PubMed ID: 19200860 [TBL] [Abstract][Full Text] [Related]
38. Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing beta-interferon therapy. Singh MK; Scott TF; LaFramboise WA; Hu FZ; Post JC; Ehrlich GD J Neurol Sci; 2007 Jul; 258(1-2):52-9. PubMed ID: 17467740 [TBL] [Abstract][Full Text] [Related]
39. Excessive biologic response to IFNβ is associated with poor treatment response in patients with multiple sclerosis. Rudick RA; Rani MR; Xu Y; Lee JC; Na J; Shrock J; Josyula A; Fisher E; Ransohoff RM PLoS One; 2011; 6(5):e19262. PubMed ID: 21602934 [TBL] [Abstract][Full Text] [Related]
40. Pharmacogenomics of responsiveness to interferon IFN-beta treatment in multiple sclerosis: a genetic screen of 100 type I interferon-inducible genes. Cunningham S; Graham C; Hutchinson M; Droogan A; O'Rourke K; Patterson C; McDonnell G; Hawkins S; Vandenbroeck K Clin Pharmacol Ther; 2005 Dec; 78(6):635-46. PubMed ID: 16338279 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]